⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13381376 | 0.77 | — | — | |
| SCHEMBL11983545 | 0.71 | — | — | |
| SCHEMBL12640352 | 0.71 | — | — | |
| SCHEMBL121602 | 0.70 | — | — | |
| SCHEMBL8959398 | 0.70 | — | — | |
| SCHEMBL17867027 | 0.69 | NOS2 (0.39) | — | |
| SCHEMBL13970901 | 0.66 | NPSR1 (0.47) | — | |
| SCHEMBL11863347 | 0.65 | MAPT (0.62) | — | |
| SCHEMBL5150721 | 0.65 | — | — | |
| SCHEMBL1013400 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229771-B1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2024-04-03 | — | — | EP | disclosed |
| US-11643413-B2 | 9-(2-oxacycloalkyl)-9H-purine-2,6-diamine derivatives and their use for the treatment of skin disorders | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2023-05-09 | — | — | US | disclosed |
| EP-3615535-B1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIV PALACKEHO (CZ) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20200157105-A1 | 9-(2-OXACYCLOALKYL)-9H-PURINE-2,6-DIAMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-05-21 | — | — | US | disclosed |
| EP-3229772-B1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIV PALACKEHO (CZ) | 2020-04-29 | — | — | EP | disclosed |
| US-10550144-B2 | 6-aryl-9-glycosylpurines and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-02-04 | — | — | US | disclosed |
| US-10100077-B2 | 6-aryl-9-glycosylpurines and use thereof | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2018-10-16 | — | — | US | disclosed |
| US-20180098952-A1 | INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA | NORTHWESTERN UNIVERSITY (US) | 2018-04-12 | — | — | US | disclosed |
| US-20170334943-A1 | 6-ARYL-9-GLYCOSYLPURINES AND USE THEREOF | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2017-11-23 | — | — | US | disclosed |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-12-10 | — | — | US | disclosed |
| EP-0381141-B1 | Novel aryl- or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions | MERRELL DOW PHARMA (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0295742-B1 | NOVEL N-(4-PIPERIDINYL) BICYCLIC CONDENSED 2-IMIDAZOLAMINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-26 | — | — | EP | disclosed |
| US-5041554-A | Replace steroids in treatment of inflammatory diseases | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-08-20 | — | — | US | disclosed |
| US-5039695-A | Method of using aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds in the treatment of interleukin-1 mediated conditions | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-08-13 | — | — | US | disclosed |
| US-5006527-A | Antihistamines, antiallergens | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-04-09 | — | — | US | disclosed |
| EP-0381141-A2 | Novel aryl- or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds useful in treating interleukin-1 mediated conditions | MERRELL PHARMACEUTICALS INC. (US) | 1990-08-08 | — | — | EP | disclosed |
| EP-0381142-A2 | Method of using aryl-or heteroaryl-1-alkyl-pyrrole-2-carboxylic acid compounds in the treatment of interleukin-1 mediated conditions | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-08-08 | — | — | EP | disclosed |
| US-4897401-A | N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives useful in treating allergic diseases | JANSSEN PHARMACEUTICAL N.V. (BE) | 1990-01-30 | — | — | US | disclosed |
| EP-0295742-A1 | Novel N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-12-21 | — | — | EP | disclosed |